Skip to main content

Clinical Trials Using Fluorouracil

Review the clinical trials studying fluorouracil on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 126-150 of 170

MnSOD Mimetic BMX-001 in Treating Patients with Anal Cancer Undergoing Radiation Therapy and Chemotherapy
Status: Active
Location: University of Nebraska Medical Center, Omaha, Nebraska
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Status: Active
Location: USC / Norris Comprehensive Cancer Center, Los Angeles, California
Erlotinib, Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Basal-Like Pancreatic Cancer, PANGEA Trial
Status: Active
Location: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
NBTXR3 Activated by Radiation Therapy for the Treatment of Locally Advanced or Borderline-Resectable Pancreatic Cancer
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Fluorouracil with or without Imiquimod for the Treatment of Squamous Cell Carcinoma of the Lower Extremities
Status: Active
Location: UPMC-Saint Margaret, Pittsburgh, Pennsylvania
Intraperitoneal Oxaliplatin and Fluorouracil for the Treatment of Patients with Peritoneal Metastases from Colorectal Cancer
Status: Active
Location: 2 locations
Chemotherapy with Radiation for the Treatment of Rectal Cancer
Status: Active
Location: UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas
Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
ProAgio with Fluorouracil, Irinotecan, and Bevacizumab for the Treatment of Advanced or Metastatic Colorectal Cancer
Status: Active
Location: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama
Zunsemetinib with mFOLFIRINOX for the Treatment of Advanced or Metastatic Pancreatic Ductal Adenocarcinoma
Status: Active
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Adaptive Radiation Therapy Boost for the Treatment of Rectal Cancer, The ARBOR Trial
Status: Active
Location: Fox Chase Cancer Center, Philadelphia, Pennsylvania
Tislelizumab and Pamiparib in Combination with Concurrent Chemotherapy and Radiation Therapy for the Treatment of Patients with Previously Treated Recurrent Head and Neck Squamous Cell Carcinoma
Status: Active
Location: University of Chicago Comprehensive Cancer Center, Chicago, Illinois
Aldesleukin in Combination with Nivolumab and Standard Chemotherapy for the Treatment of Gastric Cancer with Peritoneal Metastasis, CONTROL Study
Status: Active
Location: Mayo Clinic in Rochester, Rochester, Minnesota
Short Course Radiation Therapy and Combination Chemotherapy for the Treatment of Stage II-III Rectal Cancer
Status: Active
Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California
gFOLFOXIRITAX Regimen for the Treatment of Locally Advanced or Metastatic Upper Gastrointestinal Adenocarcinoma, I-FLOAT Study
Status: Active
Location: University of Chicago Comprehensive Cancer Center, Chicago, Illinois
Intraperitoneal Paclitaxel with NALIRIFOX for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Ductal Adenocarcinoma with Peritoneal Carcinomatosis
Status: Active
Location: UCHealth University of Colorado Hospital, Aurora, Colorado
Neoadjuvant Chemotherapy Combined with Magnetic Resonance Image Guided Pelvic Adaptive Radiation Therapy for the Treatment of Locally Advanced Rectal Cancer, SMART TNT Study
Status: Active
Location: University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida
A Response-Guided Neoadjuvant Treatment Approach for Treating Stage Ib-III Stomach or Gastroesophageal Junction Cancer, RANT-GC Trial
Status: Active
Location: UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California
CBP-1019 with FOLFOX with or without Bevacizumab, Pembrolizumab, or Enzalutamide for the Treatment of Metastatic Solid Tumors of Epithelial Origin
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Combination Chemotherapy and Bevacizumab with the NovoTTF-100L/ NovoTTF-200T System in Treating Patients with Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Adaptive, Individualized Dose Escalation of the FOX Regimen for the Treatment of Metastatic or Locally Advanced/Inoperable Gastrointestinal Cancer
Status: Active
Location: Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center, Lebanon, New Hampshire
Adaptive Radiotherapy for the Treatment of Patients with Locally Advanced Anal Cancer
Status: Active
Location: NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York
Circulating Tumor DNA for Risk Determination and Treatment Selection in Patients with Carcinomatosis from Colorectal or Appendiceal Adenocarcinoma
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer
Status: Active
Location: See ClinicalTrials.gov